Prognostic significance of systemic immune inflammatory index in NSCLC: a meta-analysis

References

• Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136(5), E359–E386 (2015).
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
   PubMed Web of Science ®Google Scholar
• de Goede OM, Nachun DC, Ferraro NM et al. Population-scale tissue transcriptomics maps long non-coding RNAs to complex disease. Cell 184(10), 2633–2648; e19 (2021).
   PubMed Web of Science ®Google Scholar
• Yang R, Chang Q, Meng X et al. Prognostic value of systemic immune-inflammation index in cancer: a meta-analysis. J. Cancer 9(18), 3295–3302 (2018).
   PubMed Web of Science ®Google Scholar
• Hu B, Yang XR, Xu Y et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin. Cancer Res. 20(23), 6212–6222 (2014).
   PubMed Web of Science ®Google Scholar
• Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur. J. Epidemiol. 25(9), 603–605 (2010).
   PubMed Web of Science ®Google Scholar
• Barili F, Parolari A, Kappetein PA et al. Statistical Primer: heterogeneity, random- or fixed-effects model analyses? Interact. Cardiovasc. Thorac. Surg. 27(3), 317–321 (2018).
   PubMed Web of Science ®Google Scholar
• Herrmann D, Sinnett P, Holmes J et al. Statistical controversies in clinical research: publication bias evaluations are not routinely conducted in clinical oncology systematic reviews. Ann. Oncol. 28(5), 931–937 (2017).
   PubMed Web of Science ®Google Scholar
• Berardi R, Santoni M, Rinaldi S et al. Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small-cell lung cancer. Ann. Transl. Med. 7(20), 572 (2019).
   PubMed Web of Science ®Google Scholar
• Bilgetekin I, Basal FB. Systemic immune-inflammation index is the best prognostic factor in patients with advanced stage adenocarcinoma of the lung treated with pemetrexed. J. Coll. Physicians Surg. Pak. 30(9), 933–939 (2020).
   PubMed Web of Science ®Google Scholar
• Coutu BG, Johnson KC, Bhirud A et al. Systemic immune-inflammatory index association with survival in patients undergoing trimodality therapy for lung cancer. Oncology 100(5), 247–256 (2022).
   PubMed Web of Science ®Google Scholar
• Delikgoz SE, Kemal Y, Karacin C et al. Prognostic impact of immune inflammation biomarkers in predicting survival and radiosensitivity in patients with non-small-cell lung cancer treated with chemoradiotherapy. J. Med. Imaging Radiat. Oncol. 66(1), 146–157 (2022).
   PubMed Web of Science ®Google Scholar
• Deng C, Zhang N, Wang Y et al. High systemic immune-inflammation index predicts poor prognosis in advanced lung adenocarcinoma patients treated with EGFR-TKIs. Medicine (Baltimore) 98(33), e16875 (2019).
   PubMed Web of Science ®Google Scholar
• Fu F, Deng C, Wen Z et al. Systemic immune-inflammation index is a stage-dependent prognostic factor in patients with operable non-small-cell lung cancer. Transl. Lung Cancer Res. 10(7), 3144–3154 (2021).
   PubMed Web of Science ®Google Scholar
• Gao Y, Zhang H, Li Y et al. Preoperative increased systemic immune-inflammation index predicts poor prognosis in patients with operable non-small-cell lung cancer. Clin. Chim. Acta 484, 272–277 (2018).
   PubMed Web of Science ®Google Scholar
• Guo D, Zhang J, Jing W et al. Prognostic value of systemic immune-inflammation index in patients with advanced non-small-cell lung cancer. Future Oncol. 14(25), 2643–2650 (2018).
   PubMed Web of Science ®Google Scholar
• Guo W, Cai S, Zhang F et al. Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected non-small-cell lung cancer. Thorac. Cancer 10(4), 761–768 (2019).
   PubMed Web of Science ®Google Scholar
• Ju Q, Huang T, Zhang Y et al. Systemic immune-inflammation index predicts prognosis in patients with different EGFR-mutant lung adenocarcinoma. Medicine (Baltimore) 100(6), e24640 (2021).
   PubMed Web of Science ®Google Scholar
• Keit E, Coutu B, Zhen W et al. Systemic inflammation is associated with inferior disease control and survival in stage III non-small-cell lung cancer. Ann. Transl. Med. 9(3), 227 (2021).
   PubMed Web of Science ®Google Scholar
• Li A, Mu X, He K et al. Prognostic value of lymphocyte-to-monocyte ratio and systemic immune-inflammation index in non-small-cell lung cancer patients with brain metastases. Future Oncol. 16(30), 2433–2444 (2020).
   PubMed Web of Science ®Google Scholar
• Li B, Wang S, Li C et al. The kinetic changes of systemic inflammatory factors during bevacizumab treatment and its prognostic role in advanced non-small-cell lung cancer patients. J. Cancer 10(21), 5082–5089 (2019).
   PubMed Web of Science ®Google Scholar
• Li H, Wang G, Zhang H et al. Prognostic role of the systemic immune-inflammation index in brain metastases from lung adenocarcinoma with different EGFR mutations. Genes Immun. 20(6), 455–461 (2019).
   PubMed Web of Science ®Google Scholar
• Li W, Qu Y, Wen F et al. Prognostic nutritional index and systemic immune-inflammation index are prognostic biomarkers for non-small-cell lung cancer brain metastases. Biomark Med. 15(13), 1071–1084 (2021).
   PubMed Web of Science ®Google Scholar
• Li X, Hu P, Liu J et al. Systemic immune-inflammation index predicted overall survival and radiosensitivity in advanced non-small-cell lung cancer. Future Oncol. 16(5), 103–115 (2020).
   PubMed Web of Science ®Google Scholar
• Liu J, Li S, Zhang S et al. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab. J. Clin. Lab. Anal. 33(8), e22964 (2019).
   PubMed Web of Science ®Google Scholar
• Shen YJ, Qian LQ, Ding ZP et al. Prognostic value of inflammatory biomarkers in patients with stage I lung adenocarcinoma treated with surgical dissection. Front Oncol. 11, 711206 (2021).
   PubMedGoogle Scholar
• Takeda T, Yamada T, Tanimura K et al. Prognostic markers of survival among japanese patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer receiving first-line alectinib. Diagnostics (Basel) 11(12), 2170 (2021).
   PubMedGoogle Scholar
• Tomita M, Ayabe T, Maeda R et al. Systemic immune-inflammation index predicts survival of patients after curative resection for non-small-cell lung cancer. In Vivo 32(3), 663–667 (2018).
   PubMed Web of Science ®Google Scholar
• Tong YS, Tan J, Zhou XL et al. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small-cell lung cancer. J. Transl. Med. 15(1), 221 (2017).
   PubMed Web of Science ®Google Scholar
• Watanabe K, Noma D, Masuda H et al. Preoperative inflammation-based scores predict early recurrence after lung cancer resection. J. Thorac. Dis. 13(5), 2812–2823 (2021).
   PubMed Web of Science ®Google Scholar
• Xu S, Cao S, Yu Y. High systemic immune-inflammation index is a predictor of poor prognosis in patients with nonsmall cell lung cancer and bone metastasis. J. Cancer Res. Ther. 17(7), 1636–1642 (2021).
   PubMed Web of Science ®Google Scholar
• Yan X, Li G. Preoperative systemic immune-inflammation index predicts prognosis and guides clinical treatment in patients with non-small-cell lung cancer. Biosci. Rep. 40(3), BSR20200352 (2020).
   PubMedGoogle Scholar
• Zhang Y, Chen Z, Jin F et al. The value of the systemic immune-inflammation index in predicting survival outcomes in patients with brain metastases of non-small-cell lung cancer treated with stereotactic radiotherapy. Mediators Inflamm. 2021, 2910892 (2021).
   PubMedGoogle Scholar
• Yajun E, He N, Wang Y et al. Percutaneous transluminal angioplasty (PTA) alone versus PTA with balloon-expandable stent placement for short-segment femoropopliteal artery disease: a metaanalysis of randomized trials. J. Vasc. Interv. Radiol. 19(4), 499–503 (2008).
   PubMed Web of Science ®Google Scholar
• Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity 51(1), 27–41 (2019).
   PubMed Web of Science ®Google Scholar
• Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 357(9255), 539–545 (2001).
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A et al. Cancer-related inflammation. Nature 454(7203), 436–444 (2008).
   PubMed Web of Science ®Google Scholar
• Cho WC, Kwan CK, Yau S et al. The role of inflammation in the pathogenesis of lung cancer. Expert Opin. Ther. Targets 15(9), 1127–1137 (2011).
   PubMed Web of Science ®Google Scholar
• Liao C, Yu Z, Guo W et al. Prognostic value of circulating inflammatory factors in non-small-cell lung cancer: a systematic review and meta-analysis. Cancer Biomark. 14(6), 469–481 (2014).
   PubMed Web of Science ®Google Scholar
• Jin Y, Sun Y, Shi X et al. Prognostic value of circulating C-reactive protein levels in patients with non-small-cell lung cancer: a systematic review with meta-analysis. J. Cancer Res. Ther. 10(Suppl.), C160–C166 (2014).
   PubMedGoogle Scholar
• Zhang N, Jiang J, Tang S et al. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Int. Immunopharmacol. 85, 106677 (2020).
   PubMed Web of Science ®Google Scholar
• Jiang T, Bai Y, Zhou F et al. Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors. Lung Cancer 130, 76–83 (2019).
   PubMed Web of Science ®Google Scholar
• Zhang H, Gao L, Zhang B et al. Prognostic value of platelet to lymphocyte ratio in non-small-cell lung cancer: a systematic review and meta-analysis. Sci. Rep. 6, 22618 (2016).
   PubMed Web of Science ®Google Scholar
• Gu X, Sun S, Gao XS et al. Prognostic value of platelet to lymphocyte ratio in non-small-cell lung cancer: evidence from 3,430 patients. Sci. Rep. 6, 23893 (2016).
   PubMed Web of Science ®Google Scholar
• Zhao QT, Yuan Z, Zhang H et al. Prognostic role of platelet to lymphocyte ratio in non-small-cell lung cancers: a meta-analysis including 3,720 patients. Int. J. Cancer 139(1), 164–170 (2016).
   PubMed Web of Science ®Google Scholar
• Tong YS, Tan J, Zhou XL et al. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small-cell lung cancer. J. Transl. Med. 15(1), 221 (2017).
   PubMed Web of Science ®Google Scholar
• Guo W, Cai S, Zhang F et al. Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected non-small-cell lung cancer. Thorac. Cancer 10(4), 761–768 (2019).
   PubMed Web of Science ®Google Scholar
• Teramukai S, Kitano T, Kishida Y et al. Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03. Eur. J. Cancer 45(11), 1950–1958 (2009).
   PubMed Web of Science ®Google Scholar
• Huang H, Li L, Luo W et al. Lymphocyte percentage as a valuable predictor of prognosis in lung cancer. J. Cell Mol. Med. 26(7), 1918–1931 (2022).
   PubMed Web of Science ®Google Scholar
• Yuan Y, Zhong H, Ye L et al. Prognostic value of pretreatment platelet counts in lung cancer: a systematic review and meta-analysis. BMC Pulm. Med. 20(1), 96 (2020).
   PubMed Web of Science ®Google Scholar
• Shui Y, Li M, Su J et al. Prognostic and clinicopathological significance of systemic immune-inflammation index in pancreatic cancer: a meta-analysis of 2,365 patients. Aging (Albany NY) 13(16), 20585–20597 (2021).
   PubMedGoogle Scholar
• Wang Y, Li Y, Chen P et al. Prognostic value of the pretreatment systemic immune-inflammation index (SII) in patients with non-small-cell lung cancer: a meta-analysis. Ann. Transl. Med. 7(18), 433 (2019).
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen B, Wang L et al. Systemic immune-inflammation index is a promising noninvasive marker to predict survival of lung cancer: a meta-analysis. Medicine (Baltimore) 98(3), e13788 (2019).
   PubMed Web of Science ®Google Scholar
• Li X, Gu L, Chen Y et al. Systemic immune-inflammation index is a promising non-invasive biomarker for predicting the survival of urinary system cancers: a systematic review and meta-analysis. Ann. Med. 53(1), 1827–1838 (2021).
   PubMed Web of Science ®Google Scholar
• Zhang Y, Lin S, Yang X et al. Prognostic value of pretreatment systemic immune-inflammation index in patients with gastrointestinal cancers. J. Cell. Physiol. 234(5), 5555–5563 (2019).
   PubMed Web of Science ®Google Scholar
• Zahorec R. Neutrophil-to-lymphocyte ratio, past, present and future perspectives. Bratisl. Lek. Listy 122(7), 474–488 (2021).
   PubMed Web of Science ®Google Scholar
• Punjabi A, Barrett E, Cheng A et al. Neutrophil-lymphocyte ratio and absolute lymphocyte count as prognostic markers in patients treated with curative-intent radiotherapy for non-small-cell lung cancer. Clin. Oncol. (R Coll Radiol.) 33(8), e331–e338 (2021).
   PubMed Web of Science ®Google Scholar
• Huang Q, Diao P, Li CL et al. Preoperative platelet-lymphocyte ratio is a superior prognostic biomarker to other systemic inflammatory response markers in non-small-cell lung cancer. Medicine (Baltimore) 99(4), e18607 (2020).
   PubMed Web of Science ®Google Scholar